RT Journal Article
SR Electronic
T1 Association between ABO blood groups and clinical outcome of coronavirus disease 2019: Evidence from two cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20063107
DO 10.1101/2020.04.15.20063107
A1 Zeng, Xianfei
A1 Fan, Hongyan
A1 Lu, Dongxue
A1 Huang, Fang
A1 Meng, Xi
A1 Li, Zhuo
A1 Tang, Mei
A1 Zhang, Jing
A1 Liu, Nannan
A1 Liu, Zhixin
A1 Zhao, Jingya
A1 Yin, Wen
A1 An, Qunxing
A1 Zhang, Xijing
A1 Hu, Xingbin
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.15.20063107.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the third most common coronavirus that causes large-scale infections worldwide. The correlations between pathogen susceptibility and blood type distribution have attracted attention decades ago. The current retrospective study aimed to examine the correlation between blood type distribution and SARS-CoV-2 infection, progression, and prognosis in patients with coronavirus disease 2019 (COVID-19). With 265 patients from multiple medical centers and two established cohorts, we found that the blood type A population was more sensitive to SARS-CoV-2. Moreover, the blood type distribution was not relevant to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality in COVID-19 patients. These findings are indicative of coping with the great threat since it probed the relationship between blood types and ARDS, AKI, and mortality, in addition to susceptibility in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding support.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this article.